Connected Health Devices Support Hypertension Management
|
By HospiMedica International staff writers Posted on 17 Sep 2018 |
|
Image: The ULTRACONNECT blood pressure monitors and connected devices (Photo courtesy of A&D Medical).
New premium smart monitors promote better blood pressure (BP) control by allowing users to share data with healthcare providers.
The A&D Medical (San Jose, CA, USA) ULTRACONNECT blood pressure monitors offer a range of features and capabilities, including a sleek, tubeless design that slips easily onto the wrist or arm; a bright organic light-emitting diode (OLED) display that provides illuminated BP feedback to the user; a light-weight, compact design that allows users to transport the device wherever they go, ensuring consistent tracking of blood pressure readings; and multi-user support functionality for up to five regular users plus an anonymous guest.
Users can operate, access data, and share their BP results via Smart Connect, an automatic feature that detects and connects the monitor to the proprietary A&D Connect app, which is designed to enhance the end-user experience with engaging, easy-to-use features such as graphing, trending, unlimited memory, reminders, and goal setting. In addition, an offline, stand-alone setup allows for transfer of up to 100 readings to the A&D Connect app at a later time. A&D Connect offers robust compatibility with both iOS and Android devices.
“The recent change in hypertension guidelines from the AHA underscores the need for more consumers to monitor and understand their own blood pressure readings. That means providing patients with the right tools to make it extremely easy to self-monitor on a regular basis, so they can make changes in their own lives to reduce hypertension-related risks,” said Terry Duesterhoeft, President and CEO of A&D Medical. “The new product line leverages our more than four decades of experience in designing and delivering connected products to both the consumer and healthcare spaces.”
The 2014 AHA BP recommendations, issued by an expert panel appointed to the Eighth Joint National Committee, suggest that for most hypertensive individuals 60 or older, pharmacologic treatment should be started when systolic BP is 150 mm Hg or higher or diastolic BP is 90 mm Hg or higher, with the goal of achieving readings below those cutoffs. For younger patients and for those with chronic kidney disease or diabetes, (regardless of age) treatment should be initiated when systolic BP is 140 or higher or diastolic BP is 90 or higher.
Related Links:
A&D Medical
The A&D Medical (San Jose, CA, USA) ULTRACONNECT blood pressure monitors offer a range of features and capabilities, including a sleek, tubeless design that slips easily onto the wrist or arm; a bright organic light-emitting diode (OLED) display that provides illuminated BP feedback to the user; a light-weight, compact design that allows users to transport the device wherever they go, ensuring consistent tracking of blood pressure readings; and multi-user support functionality for up to five regular users plus an anonymous guest.
Users can operate, access data, and share their BP results via Smart Connect, an automatic feature that detects and connects the monitor to the proprietary A&D Connect app, which is designed to enhance the end-user experience with engaging, easy-to-use features such as graphing, trending, unlimited memory, reminders, and goal setting. In addition, an offline, stand-alone setup allows for transfer of up to 100 readings to the A&D Connect app at a later time. A&D Connect offers robust compatibility with both iOS and Android devices.
“The recent change in hypertension guidelines from the AHA underscores the need for more consumers to monitor and understand their own blood pressure readings. That means providing patients with the right tools to make it extremely easy to self-monitor on a regular basis, so they can make changes in their own lives to reduce hypertension-related risks,” said Terry Duesterhoeft, President and CEO of A&D Medical. “The new product line leverages our more than four decades of experience in designing and delivering connected products to both the consumer and healthcare spaces.”
The 2014 AHA BP recommendations, issued by an expert panel appointed to the Eighth Joint National Committee, suggest that for most hypertensive individuals 60 or older, pharmacologic treatment should be started when systolic BP is 150 mm Hg or higher or diastolic BP is 90 mm Hg or higher, with the goal of achieving readings below those cutoffs. For younger patients and for those with chronic kidney disease or diabetes, (regardless of age) treatment should be initiated when systolic BP is 140 or higher or diastolic BP is 90 or higher.
Related Links:
A&D Medical
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Immobilization System
Cranial 4Pi Immobilization
New
Vessel Sealing Instrument
ERGOseal
Latest Critical Care News
- Automated IV Labeling Solution Improves Infusion Safety and Efficiency
- First-Of-Its-Kind AI Tool Detects Pulmonary Hypertension from Standard ECGs
- 4D Digital Twin Heart Model Improves CRT Outcomes
- AI Turns Glucose Data Into Actionable Insights for Diabetes Care
- Microscale Wireless Implant Tracks Brain Activity Over Time
- Smart Mask Delivers Continuous, Battery-Free Breath Monitoring
- Routine Blood Pressure Readings May Identify Risk of Future Cognitive Decline
- CGM-Based Algorithm Enhances Insulin Dose Adjustment in Type 2 Diabetes
- Fish Scale–Based Implants Offer New Approach to Corneal Repair
- Dual-Function Wound Patch Combines Infection Sensing and Treatment
- Smartwatch Signals and Blood Tests Team Up for Early Warning on Insulin Resistance
- Smart Fabric Technology Aims to Prevent Pressure Injuries in Hospital Care
- Standardized Treatment Algorithm Improves Blood Pressure Control
- Combined Infection Control Strategy Limits Drug-Resistant Outbreak in NICU
- AI Helps Predict Which Heart-Failure Patients Will Worsen Within a Year
- Algorithm Allows Paramedics to Predict Brain Damage Risk After Cardiac Arrest
Channels
Artificial Intelligence
view channel
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read more
New AI Approach Monitors Brain Health Using Passive Wearable Data
Brain health spans cognitive and emotional functions and can fluctuate even in adults without diagnosed disease. Detecting early changes remains difficult in routine care and burdens specialty services... Read more
Surgical Techniques
view channel
Continuous Monitoring with Wearables Enhances Postoperative Patient Safety
Postoperative hypoxemia on general surgical wards is common and often missed by intermittent vital sign checks. Undetected low oxygen levels can delay recovery and raise the risk of complications that... Read more
New Approach Enables Customized Muscle Tissue Without Biomaterial Scaffolds
Volumetric muscle loss is a traumatic loss of skeletal muscle that often leads to permanent functional impairment and limited reconstructive options. Current experimental strategies struggle to deliver... Read more
Patient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Health IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Business
view channel
GE HealthCare Leads Major European Initiative to Advance Cardio-Oncology Care
Cardiovascular complications are increasingly recognized among people undergoing or recovering from cancer treatment, driven by pre‑existing disease and the cardiotoxic effects of chemotherapy, radiotherapy,... Read more
